What Arrowhead Pharmaceuticals Investors (ARWR) Should Keep in Mind

By Emilio Sanchez • Thursday, December 29 12:00 • Permanent Link

We're taking a closer look at Arrowhead Pharmaceuticals today, whose shares moved 6.2% compared to 1.9% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Arrowhead Pharmaceuticals has moved -44.2% over the last year compared to -20.8% for the S&P 500 -- a difference of -23.4%
ARWR has an average analyst rating of buy and is -42.78% away from its mean target price of $69.69 per share
Its trailing 12 month earnings per share (Eps) is $-1.07
Arrowhead Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -37.1 while the S&P 500 average is 15.97
Its forward earnings per share (Eps) is $-3.08 and its forward P/E ratio is -12.9
ARWR has a Price to Earnings Growth (PEG) ratio of -2.93, which shows the company is fairly valued compared to its earnings.
The company has a Price to Book (P/B) ratio of 10.6 in contrast to the S&P 500's average ratio of 2.95
Arrowhead Pharmaceuticals is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
Arrowhead Pharmaceuticals has on average reported free cash flows of $3,109,854.00 over the last four years, during which time they have grown by an an average of -52.3%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.